TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32060665

Group type: EXPERIMENTAL
Intervention: Uncoated granules of doravirine, lamivudine, and TDF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coated doravirine granules
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Uncoated and coated doravirine granules with pudding
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doravirine granules with apple sauce
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lamivudine granules with pudding or apple sauce
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir granules with pudding or apple sauce
Number of subjects: 24
Study: 35624408

Group type: EXPERIMENTAL
Intervention: Eliapixant 10 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Eliapixant 50 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Eliapixant 200 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Eliapixant 750 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 34323019

Group type: EXPERIMENTAL
Intervention: Accelerated approval pathway
Number of subjects: 125

Group type: COMPARATOR
Intervention: Regular approval pathway
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Overall survival endpoints
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: WCLFU exceeding FI
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Magnitude of effect
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 1:1 randomization
Number of subjects: 125
Study: 35813621

Group type: EXPERIMENTAL
Intervention: Prediction equations for visceral fat area (VFA) based on age, waist circumference (WC), and neck circumference (NC) for men: VFA=3.7×age+2.4×WC+5.5×NC‐443.6
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Prediction equations for visceral fat area (VFA) based on age, waist circumference (WC), and neck circumference (NC) for women: VFA=2.8×age+1.7×WC+6.5×NC‐367.3
Number of subjects: 721
Study: 33419167

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without kinesio taping (NKT)
Number of subjects: 100
Study: 34581911

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release capsules (viloxazine ER; Qelbree™) 100-600 mg/day
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release capsules (viloxazine ER; Qelbree™)
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1354
Study: 33350762

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Add-on therapy
Number of subjects: 55
Study: 34953433

Group type: EXPERIMENTAL
Intervention: Cardiovascular resonance breathing (0.1 Hz/6 breaths per minute)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham breathing (∼0.23 Hz/14 breaths per minute)
Number of subjects: 57
Study: 32918337

Group type: EXPERIMENTAL
Intervention: Calystegines (specifically calystegine A3) measured in urine after potato consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled food intervention study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calystegine biomarkers
Number of subjects: 0
Study: 35344784

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily for 180 days
Number of subjects: 312

Group type: COMPARATOR
Intervention: No rosuvastatin (control)
Number of subjects: 312
Study: 32024944

Group type: EXPERIMENTAL
Intervention: Pharmacogenetics dosing
Number of subjects: 263

Group type: COMPARATOR
Intervention: Standard dosing
Number of subjects: 263
Study: 36629127

Group type: EXPERIMENTAL
Intervention: Organizational Process Improvement Intervention (OPII)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Early condition
Number of subjects: 21

Group type: COMPARATOR
Intervention: Delayed condition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low levels of leadership with high staff responsiveness
Number of subjects: 21
Study: 33435918

Group type: EXPERIMENTAL
Intervention: Preventive ceftriaxone
Number of subjects: 1480

Group type: EXPERIMENTAL
Intervention: Presence of CAS ≥50%
Number of subjects: 1480
Study: 32757545

Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose (SMBG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: As-usual treatment (Control Group)
Number of subjects: 54
Study: 34348355

Group type: EXPERIMENTAL
Intervention: First-line drugs for neuropathic pain
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Positive studies
Number of subjects: 107

Group type: COMPARATOR
Intervention: Negative studies
Number of subjects: 107
Study: 32854094

Group type: EXPERIMENTAL
Intervention: Transgenic rice (80 g) administered orally for 20 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transgenic rice (5 g and 20 g) administered orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transgenic rice (80 g) administered orally
Number of subjects: 0
Study: 32060552

Group type: EXPERIMENTAL
Intervention: Cognitive distraction (DIS) during meal consumption (n = 55)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (CON) without distraction (n = 64)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cognitive distraction (DIS)
Number of subjects: 119
Study: 34561057

Group type: EXPERIMENTAL
Intervention: Postpartum mobile support application
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 124
Study: 32493447

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg tablet, 2 tablets daily for 1 to 3 months
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo (similar in form and taste to hydroxychloroquine)
Number of subjects: 282
Study: 35766564

Group type: EXPERIMENTAL
Intervention: Minimally Processed Diet (MPD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chinese Government-Recommended Diet (GRD)
Number of subjects: 60
Study: 34793746

Group type: EXPERIMENTAL
Intervention: Adjustable intragastric balloon (aIGB) with lifestyle intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control (lifestyle intervention alone)
Number of subjects: 288
Study: 35261113

Group type: EXPERIMENTAL
Intervention: Mindfulness training group (TG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group (ACG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention control group (NCG)
Number of subjects: 0
Study: 33361495

Group type: EXPERIMENTAL
Intervention: Multicomponent training with traditional exercise and exergaming, twice a week for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional exercise sessions (active control group)
Number of subjects: 31
Study: 36109006

Group type: EXPERIMENTAL
Intervention: Temporal inverted ILM flap technique
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional ILM peeling (control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 65
Study: 33422659

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 61

Group type: COMPARATOR
Intervention: No pessary
Number of subjects: 61
Study: 34450687

Group type: EXPERIMENTAL
Intervention: Lateral injection technique with a high G prime filler
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional technique with a low G prime filler
Number of subjects: 30
Study: 32592578

Group type: EXPERIMENTAL
Intervention: Antigravity treadmill (AGT) combined with conventional rehabilitation (CR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 45
Study: 35099294

Group type: EXPERIMENTAL
Intervention: Closed loop control (CLC) insulin delivery
Number of subjects: 16
Study: 34322552

Group type: EXPERIMENTAL
Intervention: ABC method
Number of subjects: 1937

Group type: COMPARATOR
Intervention: 5As method
Number of subjects: 1937
Study: 36355674

Group type: EXPERIMENTAL
Intervention: Gift giving (Study 1)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Written note of appreciation to a close other (Study 2)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Gift keeping (Study 1)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Neutral control task (Study 1)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Written reflection of a time when they received social support (Study 2)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Neutral control task (Study 2)
Number of subjects: 574
Study: 33499876

Group type: EXPERIMENTAL
Intervention: Self-completed EQ-5D-5L
Number of subjects: 120

Group type: COMPARATOR
Intervention: Proxy-patient version of EQ-5D-5L
Number of subjects: 120

Group type: COMPARATOR
Intervention: Proxy-proxy version of EQ-5D-5L
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: VAS-Health score from patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: VAS-Health score from proxy-proxy perspective
Number of subjects: 120

Group type: COMPARATOR
Intervention: VAS-Health score from proxy-patient perspective
Number of subjects: 120
Study: 35879211

Group type: EXPERIMENTAL
Intervention: Reality television-style singing
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Amateur singing
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Professional plain singing
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control version (piano, no singing)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Professional singing in the style of reality television singing
Number of subjects: 212
Study: 34242101

Group type: EXPERIMENTAL
Intervention: 2'-O-methoxyethyl (2?MOE) modified ASOs
Number of subjects: 713

Group type: COMPARATOR
Intervention: Mipomersen (control)
Number of subjects: 713
Study: 35050303

Group type: EXPERIMENTAL
Intervention: EBRT
Number of subjects: 3410

Group type: EXPERIMENTAL
Intervention: EBRT+BT
Number of subjects: 3410

Group type: COMPARATOR
Intervention: EBRT (DART)
Number of subjects: 3410
Study: 33314365

Group type: EXPERIMENTAL
Intervention: New model for predicting AKI
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: New model
Number of subjects: 848

Group type: COMPARATOR
Intervention: Cleveland Clinic score
Number of subjects: 848

Group type: COMPARATOR
Intervention: Simplified Renal Index (SRI) score
Number of subjects: 848
Study: 36250257

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33389313

Group type: EXPERIMENTAL
Intervention: 1.0-mg/kg/day Tripterygium wilfordii Hook F. (TwHF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.5-mg/kg/day Tripterygium wilfordii Hook F. (TwHF)
Number of subjects: 30
Study: 35932954

Group type: EXPERIMENTAL
Intervention: Video intervention showing values communication between cancer patient-caregivers
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 34698813

Group type: EXPERIMENTAL
Intervention: Vi-polysaccharide Conjugate Vaccine
Number of subjects: 0
Study: 33782018

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention embedded into GP practice IT systems including parental concerns elicitation, prognostic algorithm results, and prescribing guidance.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 310
Study: 32652112

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations (58.8%)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Amplifications on chromosome 8p11 (10.9%)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: BRCA2 mutations (2.3%)
Number of subjects: 764
Study: 36112819

Group type: EXPERIMENTAL
Intervention: Low-velocity resistance exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-velocity resistance exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both low- and high-velocity resistance exercises
Number of subjects: 60
Study: 34515607

Group type: EXPERIMENTAL
Intervention: Checklist access
Number of subjects: 347

Group type: COMPARATOR
Intervention: No checklist access
Number of subjects: 347
Study: 33217618

Group type: EXPERIMENTAL
Intervention: PDS 10‐mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 40‐mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 100‐mg/ml
Number of subjects: 220

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5‐mg
Number of subjects: 220
Study: 32126551

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1087
Study: 32019378

Group type: EXPERIMENTAL
Intervention: EmbaGYN device (Group 1, n = 40)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Magic Kegel Master device (Group 2, n = 40)
Number of subjects: 70
Study: 34214289

Group type: EXPERIMENTAL
Intervention: Nursing Professional Values scale (NPVS‐3)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Caring domain (10 items)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Activism domain (10 items)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Professionalism domain (8 items)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Experience level of nurses
Number of subjects: 124
Study: 35288513

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) + HMB supplementation (1500 mg daily)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Education + HMB supplementation (1500 mg daily)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) + Placebo
Number of subjects: 156

Group type: COMPARATOR
Intervention: Education + Placebo
Number of subjects: 156
Study: 33246482

Group type: EXPERIMENTAL
Intervention: PK-guided dosing of hydroxyurea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard weight-based dosing of hydroxyurea (20 mg/kg/day)
Number of subjects: 0
Study: 34578981

Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (LGL) diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: High Glycemic Load (HGL) diet
Number of subjects: 12
Study: 32776933

Group type: EXPERIMENTAL
Intervention: Eating raw fish 12–50 times in the last year
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Eating raw fish >50 times in the last year
Number of subjects: 2521
Study: 36460332

Group type: EXPERIMENTAL
Intervention: Practical Anemia Bundle for Sustained Blood Recovery (PABST-BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 36271976

Group type: EXPERIMENTAL
Intervention: Behavioral Health Home Plus (BHHP) model implementation training through Learning Collaborative (LC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Learning Collaborative (LC) approach
Number of subjects: 12
Study: 33543872

Group type: EXPERIMENTAL
Intervention: Long-lasting Multidisciplinary Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32315981

Group type: EXPERIMENTAL
Intervention: Low-intensity activity breaks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate-intensity activity breaks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-intensity activity breaks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary breaks
Number of subjects: 30
Study: 35685676

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg intravenously
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg intravenously + Nalbuphine 0.2 mg/kg
Number of subjects: 110

Group type: COMPARATOR
Intervention: 0.9% Saline
Number of subjects: 110
Study: 34868333

Group type: EXPERIMENTAL
Intervention: Wenbu Zhibi Granule (WZG)
Number of subjects: 100
Study: 36477734

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 448

Group type: COMPARATOR
Intervention: Overall preference allocation
Number of subjects: 448
Study: 33413212

Group type: EXPERIMENTAL
Intervention: Professional oral care (POC)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (no professional oral care)
Number of subjects: 174
Study: 35552287

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 70
Study: 34478863

Group type: EXPERIMENTAL
Intervention: 5% topical benzoyl peroxide (BPO) gel applied for a total of 5 treatments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blue light therapy (BLT), single 23‐minute treatment at 40 mW/cm2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of BPO followed by BLT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (contralateral shoulders)
Number of subjects: 60
Study: 32317212

Group type: EXPERIMENTAL
Intervention: In-bed cycling intervention
Number of subjects: 0
Study: 35790298

Group type: EXPERIMENTAL
Intervention: Polypectomy with cutting current (PCC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 49
Study: 33811051

Group type: EXPERIMENTAL
Intervention: DCD allograft in addition to standard care
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 196
Study: 32529588

Group type: EXPERIMENTAL
Intervention: Diode laser 808 nm combined with TheraCal LC
Number of subjects: 14

Group type: COMPARATOR
Intervention: TheraCal LC alone
Number of subjects: 14
Study: 34866029

Group type: EXPERIMENTAL
Intervention: Combination therapy with low-intensity shockwave therapy (LiST) and tadalafil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35415565

Group type: EXPERIMENTAL
Intervention: Noise-canceling headphones and music during surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no headphones or music)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 33188164

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Historical control series (not specified)
Number of subjects: 203
Study: 35225793

Group type: EXPERIMENTAL
Intervention: Magnesium-based bioresorbable scaffolds (MgBRS)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Permanent metallic sirolimus-eluting stents (SES)
Number of subjects: 142
Study: 32928237

Group type: EXPERIMENTAL
Intervention: Cisplatin-sensitized radiation therapy combined with pembrolizumab
Number of subjects: 0
Study: 34413247

Group type: EXPERIMENTAL
Intervention: RD/eSLD
Number of subjects: 110

Group type: COMPARATOR
Intervention: RD/CD
Number of subjects: 110

Group type: COMPARATOR
Intervention: FTF/CD
Number of subjects: 110
Study: 33296389

Group type: EXPERIMENTAL
Intervention: subcaudal pholidosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ventral body markings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: combination of both measures
Number of subjects: 0
Study: 35943743

Group type: EXPERIMENTAL
Intervention: Acupuncture (30-minute session after 50 mg/2 mL diclofenac sodium intramuscular injection)
Number of subjects: 80
Study: 33641473

Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation (NHFOV)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: NHFOV and NIPPV
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: NHFOV
Number of subjects: 149
Study: 32425222

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) + standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 35232215

Group type: EXPERIMENTAL
Intervention: EPA+DPA-FFA
Number of subjects: 100

Group type: COMPARATOR
Intervention: EPA-EE
Number of subjects: 100
Study: 34503983

Group type: COMPARATOR
Intervention: Prednisolone monotherapy (4 months)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Prednisolone-itraconazole combination (4 and 6 months)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 191
Study: 34736499

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 34536666

Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT) for 10 minutes daily for three consecutive days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 103
Study: 34687360

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 60
Study: 32902205

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milrinone (in vivo studies in sheep)
Number of subjects: 20
Study: 35857396

Group type: EXPERIMENTAL
Intervention: Rater training intervention (in-person training followed by asynchronous online spaced learning)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rater training intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no rater training)
Number of subjects: 94
Study: 33146811

Group type: EXPERIMENTAL
Intervention: modified endoscopic retrograde appendicitis therapy (mERAT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: antibiotic treatment
Number of subjects: 83
Study: 32433915

Group type: EXPERIMENTAL
Intervention: Colonoscopy performed by a fellow under the supervision of a staff endoscopist
Number of subjects: 812

Group type: COMPARATOR
Intervention: Colonoscopy performed by an attending physician alone
Number of subjects: 812
Study: 35418080

Group type: EXPERIMENTAL
Intervention: 4 cycles of R-CHOP followed by 2 additional cycles of rituximab monotherapy for patients with negative interim PET/CT
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 4 cycles of R-CHOP
Number of subjects: 129

Group type: COMPARATOR
Intervention: 6 cycles of R-CHOP
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 4 cycles of R-CHOP followed by 2 cycles of rituximab
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Positive interim PET/CT
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Negative interim PET/CT
Number of subjects: 129
Study: 33540241

Group type: EXPERIMENTAL
Intervention: Fenfluramine at 0.7 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 0